High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.
Also called NCT03403556
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Registry
-
NCT03403556
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT03403556. Randomized; no masking; primary purpose treatment. Start 2018-03-27 (actual); primary completion 2021-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Rosuvamibe
- Intervention (Drug)
- Monorova
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct03403556- Content hash
6e5ca4a0ef2507e09fc3ac48f82c4a00c641f18d8f212b1717015fe1246cecd5